RecruitingOBSERVATIONAL

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

This study is designed to learn more about a medication called Octreotide subcutaneous depot, which is used to treat a condition called acromegaly. Instead of testing a new treatment, this is an 'observational' study. This means we're watching how people use the medication in their everyday lives, outside of strict research settings. We want to see how well it works and how safe it is over a long period, up to two years. The goal is to collect real-world information that can help doctors and patients understand more about using this specific treatment for acromegaly, ensuring it's both effective and safe for those who need it.

At a glance

Status

Recruiting

Sponsor

Camurus AB

Enrolment target

200

Start

05 Jun 2026

Estimated completion

01 Jun 2029

Acromegaly

What is this study about?

You might be hearing about a study focusing on a treatment for a condition called acromegaly. Acromegaly is a rare condition where the body makes too much growth hormone, which can cause bones and soft tissues to grow larger than they should. The study is interested in a specific medication called Octreotide subcutaneous depot, which is given as an injection under the skin.

This isn't a study where researchers are testing a brand new drug or asking people to try something unproven. Instead, it's called an 'observational' study. This means the doctors and researchers want to watch and learn about how the medication is being used by patients in their normal lives. They want to see how well it helps control acromegaly symptoms and whether it causes any side effects over a longer period, up to two years. They are interested in gathering information from people who are already using Octreotide or are about to start it as part of their regular care.

The main aim of this study is to gather 'real-world' information. This kind of information is really valuable because it shows how a medication works when people are living their daily lives, not just in a tightly controlled research environment. By collecting this information over time, up to two years, the study hopes to give us a better understanding of the long-term safety and effectiveness of Octreotide subcutaneous depot for people with acromegaly. This knowledge can help improve care for future patients.

Key takeaways

This study observes how Octreotide subcutaneous depot works for acromegaly.
It's about 'real-world' use, not testing a new drug.
You must be 18 or over and already use or start this specific medication for acromegaly.
Participation involves sharing information from your regular doctor visits.
The study lasts up to two years, with no extra appointments.
Your medical care won't change, and you can withdraw at any time.

Who may be eligible?

To join this study, you must be 18 years old or older. The main requirement is that you are either already using Octreotide subcutaneous depot to treat your acromegaly, or you are about to start using it as part of your normal treatment plan.

There are a few reasons why someone might not be able to join. For example, if you are using Octreotide subcutaneous depot for a health condition other than acromegaly, this study wouldn't be suitable for you. Also, if you are currently taking part in another clinical trial where you are given a specific treatment to test, or if you've just finished one within the last 30 days, you wouldn't be able to join this study right now.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am 18 years old or older.
I have acromegaly.
I am currently taking Octreotide subcutaneous depot for my acromegaly, or I am about to start it.
I am not taking this medication for any other condition.
I am not currently taking part in another medical trial where I am testing a new treatment.

Answer every question to see your result.

What does participation involve?

If you decide to take part in this observational study, it will mostly involve your regular doctor's appointments and treatments for your acromegaly. You won't be given a new medicine or asked to follow a special treatment plan outside of what your doctor recommends for your condition. The study team will simply collect information from your medical records about how your Octreotide treatment is progressing. This will include details about your medication, how you're feeling, and any side effects you might experience.

The study will follow you for up to two years. During this time, the study team will gather information from your routine visits and check-ups with your doctor. This means you won't have extra visits just for the study; instead, the information will come from the appointments you would have anyway. There are no extra tests or procedures required specifically for this study. The focus is on observing your treatment journey as it happens naturally.

Potential risks and benefits

Taking part in this study may not directly benefit you personally, as it mainly involves collecting information from your regular care. However, the information gathered could help improve understanding of Octreotide subcutaneous depot for acromegaly in the long run, potentially benefiting others with the condition in the future. As it's an observational study, you won't be asked to do anything different from your usual treatment, so there are no additional risks beyond those associated with your standard medical care and the medication you are already taking or starting. You are free to withdraw from the study at any time without giving a reason, and this will not affect your medical care.

Locations (6)

Universitaetsklinikum Aachen
Verified postcode
Aachen, Germany· Not yet recruiting
Universitaetsklinikum Leipzig
Verified postcode
Leipzig, Germany· Recruiting
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
Verified postcode
Magdeburg, Germany· Recruiting
Medicover Neuroendokrinologie MVZ
Verified postcode
München, Germany· Not yet recruiting
Universitätsklinikum Würzburg
Verified postcode
Würzburg, Germany· Recruiting
St James's University Hospital - Leeds Teaching Hospitals NHS Trust
Verified postcode
Leeds, United Kingdom· Not yet recruiting

Common questions

What is an 'observational' study?

It means researchers are watching how a medication is used in real life, rather than testing a new treatment or asking you to do anything different from your usual care.

Will I have to take a new medicine?

No, you will continue with your Octreotide subcutaneous depot treatment as prescribed by your own doctor. The study simply collects information about it.

How long will the study last for me?

The study will follow your treatment progress for up to two years.

Do I need extra doctor's appointments?

No, the study will gather information from your routine medical appointments, so you won't have to make extra visits just for the study.

Can I leave the study at any time?

Yes, you are free to leave the study whenever you want, and your medical care will not be affected.

How to find out more

Camurus AB

medicalinfo@camurus.com +46 46 286 57 30 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.